Page 166 - Haematologica August 2018

A. Roberto et al.
Modeling human natural killer cell develop-
ment in the era of innate lymphoid cells.
Front Immunol. 2017;8:360.
31. Melenhorst JJ, Tian X, Xu D, et al.
Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell trans- plantation. Haematologica. 2012;97(6):867- 873.
32. Mattiola I, Pesant M, Tentorio PF, et al. Priming of human resting NK cells by autol- ogous M1 macrophages via the engage- ment of IL-1b, IFN-b, and IL-15 pathways. J Immunol. 2015; 195(6):2818-2828.
33. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013;25(6):439- 448.
34. Granzin M, Wagner J, Kohl U, Cerwenka A, Huppert V, Ullrich E. Shaping of natural killer cell antitumor activity by ex vivo cul- tivation. Front Immunol. 2017;8:458.
35. Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U A. 1998;95(9):5199-5204.
36. Pesce S, Carlomagno S, Moretta A, Sivori S,
Marcenaro E. Uptake of CCR7 by KIR2DS4(+) NK cells is induced upon recognition of certain HLA-C alleles. J Immunol Res. 2015;2015:754373.
37. Blaise D, Furst S, El Cheikh J, et al. Comparison of haploidentical T-replete HSCT followed with post-transplant high dose cyclophosphamide (PT-HDCy) with matched related (MRD) or unrelated (UD) HSCT in patients in or after the 6TH decade. Biol Blood Marrow Transplant. 2015;21(2):S273-S274.
38. Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metallopro- tease-17 (ADAM17). Blood. 2013; 121(18):3599-3608.
39. Lajoie L, Congy-Jolivet N, Bolzec A, et al. ADAM17-mediated shedding of FcgammaRIIIA on human NK cells: identi- fication of the cleavage site and relation- ship with activation. J Immunol. 2014; 192(2):741-751.
40. Chan A, Hong DL, Atzberger A, et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol.
2007;179(1):89-94.
41. Boissel L, Tuncer HH, Betancur M,
Wolfberg A, Klingemann H. Umbilical cord mesenchymal stem cells increase expan- sion of cord blood natural killer cells. Biol Blood Marrow Transplant. 2008; 14(9):1031-1038.
42. Hosseini E, Ghasemzadeh M, Kamalizad M, Schwarer AP. Ex vivo expansion of CD3depleted cord blood-MNCs in the presence of bone marrow stromal cells; an appropriate strategy to provide functional NK cells applicable for cellular therapy. Stem Cell Res. 2017;19:148-155.
43. Wagner JA, Rosario M, Romee R, et al. CD56bright NK cells exhibit potent antitu- mor responses following IL-15 priming. J Clin Invest. 2017;127(11):4042-4058.
44. Ruggeri L, Urbani E, Andre P, et al. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells. Haematologica. 2016;101(5):626-633.
45. McWilliams EM, Mele JM, Cheney C, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016;5(10):e1226720.
1402
haematologica | 2018; 103(8)